|
At the American Association for Cancer Research (AACR) meeting, several major updates in lung cancer immunotherapy studies were announced and thee articles were concurrently published in the NEJM: Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden Neoadjuvant PD-1 Blockade in Resectable Lung Cancer April 16, 2018  Comments are closed.
|